ABSTRACT A significant proportion of breast cancers with HER2 amplification show simultaneous amplification or deletion of Topo 2. Amplification of Topo 2 may lead to the overexpression of the Topo 2 protein and ultimately to hypersensitivity to Topo 2 inhibitors. HER2 and Topo 2 gene status in breast cancer patients has been determined in several studies using immunohistochemistry, florescence in situ hybridisation (FISH) and multiplex ligation-dependent probe amplification (MLPA). Although comparisons of FISH and MLPA have been reported for HER2, it is believed that there are no similar studies for Topo 2. In this study, HER2 and Topo 2 were analysed by MLPA and FISH. There was a high agreement between the two approaches, although MLPA was easier to perform and cheaper than FISH. In conclusion, MLPA is a fast and accurate quantitative method to detect HER2 and Topo 2 amplification, and could be considered a good alternative to FISH.
INTRODUCTION
HER2 is a cell membrane surface-bound receptor tyrosine kinase that is normally involved in the signal transduction pathways leading to cell growth and differentiation. It is encoded by HER2/ neu, a known proto-oncogene. Reports suggest that approximately 20e30% of breast cancers have amplified HER2/neu genes or overexpression of its protein product. Because of its ability to predict response to trastuzumab (Herceptin) as well as its prognostic role, breast tumours are routinely tested for overexpression of HER 2/neu.
Topoisomerases control DNA topology by catalysing the breaking and rejoining of the phosphodiester backbone of DNA strands during the normal cell cycle. Topo 2 is a key enzyme in DNA replication, and the Topo 2 gene is located on chromosome 17q12e21, close to HER2. Amplification or deletion of Topo 2 has been observed in nearly 90% of HER2-amplified primary breast cancers, 1 while Topo 2 copy number anomalies are rare in HER2 non-amplified tumours (<7%). 2 3 In recent years, topoisomerases have become popular targets for cancer chemotherapy. It is thought that topoisomerase inhibitors block the ligation step of the cell cycle, generating single-and double-stranded breaks that affect genome integrity, leading to apoptosis and cell death. In vitro studies have indicated that sensitivity to Topo 2 inhibitors is dependent on its expression level in the target cancer cells. 4 Amplification of Topo 2 may lead to the overexpression of the Topo 2 protein and ultimately to hypersensitivity to Topo 2 inhibitors. 5 Most HER2 studies have used immunohistochemistry (IHC) to determine HER2 gene amplification; more recently, in situ hybridisation, which allows for accurate localisation of a specific segment of nucleic acid within a histological section, has been used. One of the most common in situ hybridisation techniques is dual or tricolour fluorescence in situ hybridisation (FISH), used to detect one or two genes together with the chromosome enumeration probe (CEP 17) as control.
A number of reports have shown higher accuracy of FISH and apparent superiority over IHC in predicting response to trastuzumab in metastatic breast carcinoma. 6 However, the main difficulty in adopting FISH in the clinical setting is its high cost and the need for specialised personnel for its interpretation. Another technique is chromogenic in situ hybridisation (CISH), which permits greater histological detail and is not subject to rapid fading, but again requires specialised personnel. 7 Recently, a new, high resolution method to detect copy number variation in genomic sequences, multiplex ligation-dependent probe amplification (MLPA), has been developed. MLPA has rapidly gained acceptance in genetic diagnostic laboratories due to its simplicity and similar execution time compared to other methods, and its relatively low cost, capacity for reasonably high throughput and perceived robustness. A large number of validation studies have either been published or are ongoing.
In this report, we compared the results of determination of HER2 and Topo 2 status by MLPA and FISH on a series of 20 breast cancers for HER2, and 15 for Topo 2.
METHODS Fluorescence in situ hybridisation
FISH was performed using the FDA approved PathVysion kits (Vysis, Abbott Park, Illinois, USA) for HER2, and the TOP 2A/ CEP17 FISH Probe Kit (Vysis Abbott) as previously described ( figure 1A,B; figure 2AeC ).
8e10 Samples with a gene/CEP ratio >2.2 were considered gene amplified; all those with a ratio <1.8 were considered not amplified. Chromosome polysomy was defined as the presence of more than three CEP signals per cell. Borderline FISH cases were resolved by counting additional cells.
Multiplex ligation-dependent probe amplification
MLPA was performed as previously described, 11 using the p004 HER2 kit (MRC Holland, Amsterdam), which contains three probes each for HER2 and Topo 2. PCR products were analysed by 3100-Avant Genetic Analyser (Applied Biosystems, Foster City, California, USA). HER2 and Topo 2 gene copy number was determined by considering either the first probe (1st) or by calculating the mean of the three probes for each marker. HER2 and Topo 2 gene copy number were normalised against the control probes. A more detailed analysis of individual HER2 values showed a high level of agreement with FISH results at an MLPA cut-off value of 2.0 using only the first probe (1st) (table 2). The threeprobe combination gave quite similar results (data not shown). Therefore, 100% of cases were FISH positives for MLPA cut-off values higher than 2.0.
RESULTS
For Topo 2 detection, considering only the first MLPA probe (1st), there was total agreement (100%) between FISH negative results and MLPA cut-off values <1.0 (table 3) . Conversely, using three MLPA probes, there was a 100% accuracy between FISH positive cases and an MLPA cut-off >1.4 (table 4).
DISCUSSION
HER2 and Topo 2 gene status in breast cancer patients has been determined in several studies using various methodologies, IHC, FISH and MLPA. However, analyses of results obtained with n (%)
FISH and MLPA have been reported for HER2 but not, at least at our knowledge, for Topo 2.
In our study, we analysed HER2 and Topo 2 by MLPA and FISH, observing a high agreement between the two approaches. The MLPA test was found to be accurate, even for the detection of polysomic cases, and was also easier to perform and much cheaper than FISH (about 15 euro/sample for MLPA compared to 150 euro/sample for the most widely used FISH kit commercialised by Vysis/Abbott, or 50 euro using the kit available from other suppliers). Moreover, MLPA is quantitative, not observer-dependent, and provides in a single step all the information required to decide on the best therapeutic approach.
Our MLPA results for HER2 status were similar for the first probe (1st) and the three-probe combination, in contrast to that reported by Moelans et al, 12 with an overall agreement in positivity between FISH and an MLPA cut-off value of 2.0. Conversely, for Topo 2 determination, 100% agreement between the two methods was only observed at an MLPA cut-off of 1.4 using the three probes.
In conclusion, MLPA is a fast, accurate, quantitative and cheap method to detect HER2 and Topo 2 amplification and could be considered a good alternative to FISH.
